Literature DB >> 18327979

Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay.

Tsunefusa Hayashida1, Hiroyuki Gatanaga, Junko Tanuma, Shinichi Oka.   

Abstract

The IgG-capture BED-enzyme immunoassay (BED-CEIA) is used widely at present to detect recent HIV-1 seroconversion. However, antibody levels and antibody kinetics are impacted by HIV-1 load and antiretroviral treatment, which may have a significant effect on the assay results. In this study, we analyzed serial samples from 11 patients with recent infection, including four patients treated by structured treatment interruption (STI), and compared the results with those of 10 untreated and 7 treated patients with chronic infection. The BED-CEIA missidentified one long-term nonprogressor hemophiliac with an extremely low HIV-1 load and five patients with chronic infection who received antiretroviral treatment. We also found that the ODn values increased slowly in patients with recent infection and low HIV-1 loads and that the ODn values fluctuated in parallel with HIV-1 load during STI. Our data indicate that the results of BED-CEIA are influenced by HIV-1 load and antiretroviral treatment. Care should be taken when interpreting the results of BED-CEIA, especially in individuals with low HIV-1 loads. Those on antiretroviral treatment should be excluded from BED-CEIA testing to improve the predictive value of detecting recent infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18327979     DOI: 10.1089/aid.2007.0150

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  35 in total

1.  Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay.

Authors:  Oliver Laeyendecker; Ron Brookmeyer; Amy E Oliver; Caroline E Mullis; Kevin P Eaton; Amy C Mueller; Lisa P Jacobson; Joseph B Margolick; Joelle Brown; Charles R Rinaldo; Thomas C Quinn; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2011-12-01       Impact factor: 2.205

2.  Can HIV incidence testing be used for evaluating HIV intervention programs? A reanalysis of the Orange Farm male circumcision trial (ANRS-1265).

Authors:  Agnès Fiamma; Pascale Lissouba; Oliver E Amy; Beverley Singh; Oliver Laeyendecker; Thomas C Quinn; Dirk Taljaard; Bertran Auvert
Journal:  BMC Infect Dis       Date:  2010-05-27       Impact factor: 3.090

3.  Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries.

Authors:  Oliver Laeyendecker; Ron Brookmeyer; Caroline E Mullis; Deborah Donnell; Jairam Lingappa; Connie Celum; Jared M Baeten; Mary S Campbell; Max Essex; Guy de Bruyn; Carey Farquhar; Thomas C Quinn; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10       Impact factor: 2.205

4.  Estimating False-Recent Classification for the Limiting-Antigen Avidity EIA and BED-Capture Enzyme Immunoassay in Vietnam: Implications for HIV-1 Incidence Estimates.

Authors:  Neha S Shah; Yen T Duong; Linh-Vi Le; Nguyen Anh Tuan; Bharat S Parekh; Hoang Thi Thanh Ha; Quang Duy Pham; Cao Thi Thu Cuc; Trudy Dobbs; Tran Hong Tram; Truong Thi Xuan Lien; Nick Wagar; Chunfu Yang; Amy Martin; Mitchell Wolfe; Nguyen Tran Hien; Andrea A Kim
Journal:  AIDS Res Hum Retroviruses       Date:  2017-03-13       Impact factor: 2.205

5.  HIV controllers with different viral load cutoff levels have distinct virologic and immunologic profiles.

Authors:  Fernanda H Côrtes; Caroline Pb Passaes; Gonzalo Bello; Sylvia Lm Teixeira; Carla Vorsatz; Dunja Babic; Mark Sharkey; Beatriz Grinsztejn; Valdilea Veloso; Mario Stevenson; Mariza G Morgado
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-01       Impact factor: 3.731

6.  Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay.

Authors:  Andrew F Longosz; Charles S Morrison; Pai-Lien Chen; Eric Arts; Immaculate Nankya; Robert A Salata; Veronica Franco; Thomas C Quinn; Susan H Eshleman; Oliver Laeyendecker
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

Review 7.  Diagnosis of Human Immunodeficiency Virus Infection.

Authors:  Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong
Journal:  Clin Microbiol Rev       Date:  2018-11-28       Impact factor: 26.132

8.  Short communication: effect of short-course antenatal zidovudine and single-dose nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 subtype C infection.

Authors:  Rui Wang; Jia Weng; Sikhulile Moyo; Debanjan Pain; Christopher D Barr; Dorcas Maruapula; Dineo Mongwato; Joseph Makhema; Vladimir Novitsky; M Essex
Journal:  AIDS Res Hum Retroviruses       Date:  2013-04-19       Impact factor: 2.205

9.  Prevalence, estimated HIV-1 incidence and viral diversity among people seeking voluntary counseling and testing services in Rio de Janeiro, Brazil.

Authors:  Carlos A Velasco de Castro; Beatriz Grinsztejn; Valdiléa G Veloso; Francisco I Bastos; José H Pilotto; Mariza G Morgado
Journal:  BMC Infect Dis       Date:  2010-07-28       Impact factor: 3.090

10.  Errors in 'BED'-derived estimates of HIV incidence will vary by place, time and age.

Authors:  Timothy B Hallett; Peter Ghys; Till Bärnighausen; Ping Yan; Geoff P Garnett
Journal:  PLoS One       Date:  2009-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.